| Literature DB >> 25371599 |
Joseph Schwager1, Nathalie Richard1, Rotraut Schoop1, Swen Wolfram1.
Abstract
Rose hip powder (RHP) alleviates osteoarthritis (OA) due to its anti-inflammatory and cartilage-protective properties. Substances contained in RHP might contribute to its clinical efficacy. The activity of two RHP (i.e., RH-A, from the whole fruit, RH-B, from fruits without seeds) was investigated in human peripheral blood leukocytes (PBL) and primary chondrocytes (NHAC-kn). RH-A and RH-B diminished the secretion of chemokines and cytokines in LPS/IFN-γ-activated PBL, including CCL5/RANTES, CXCL10/IP-10, interleukin- (IL-) 6, and IL-12. Most effects were transcriptional, since gene expression levels were significantly influenced by RH-A and RH-B. In IL-1β treated normal chondrocytes (NHAC-kn), both RH preparations reduced the expression of matrix metalloproteinase- (MMP-) 1, MMP-3, and MMP-13 and ADAMTS-4. These changes are associated with diminished inflammatory damage or cartilage erosion. Principal component analysis revealed that (1) RH-A and RH-B modified a large pattern of biomarkers, and (2) RH-B outperformed RH-A. Furthermore, RH-B contained more chondroprotective and anti-inflammatory constituents than RH-A. Thus, RHP contributed to restore cellular homeostasis in PBL and chondrocytes. RH preparations from fruits without seeds are thus expected to have an improved OA-preventive or OA-therapeutic profile, as subsequently shown in a related clinical trial.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25371599 PMCID: PMC4211164 DOI: 10.1155/2014/105710
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Constituents of RH-A and RH-B.
| Constituent [mg/kg] | RH-A | RH-B |
|---|---|---|
| GLGPG1 | 114 | 210 |
| MGDG2 | 71 | 120 |
| DGDG3 | 1220 | 1900 |
| Betulinic acid4 | 662 | 1078 |
| Betulinic, oleanolic, and ursolic acid | 1060 | 1711 |
| Vitamin C | 3146 | 3182 |
| Vitamin E | 129 | 212 |
| Total carotenoids | 190 | 250 |
|
| 36 | 36 |
| Lycopene | 89 | 137 |
| Total fatty acid | 32810 | 7360 |
| Linoleic acid | 16390 | 2230 |
| EPA | <LOD5 | 80 |
| DHA | <LOD | 60 |
1Galacto-lipid (2S)-1, 2-di-O-[(9Z, 12Z, 15Z)-octadeca-9, 12, 15-trienoyl]-3-O-β-D-galactopyranosyl glycerol.
2Mono-galactosyl diglyceride.
3Di-galactosyl diglyceride.
4Betulinic acid, oleanolic acid, and ursolic acid were determined according to a validated in-house method; vitamin C and vitamin E were analyzed according to the official methods EN14130 and EN12822, respectively; linoleic acid, EPA, and DHA were measured according to the official method of ISO 12966-2.
5Limits of detection.
Secretion of proteins by activated PBL. LPS/IFN-γ-stimulated cells were cultured with 125–500 μg/mL RHP for 24 h and proteins were quantified by multiparametric analysis. Only values for (LPS/IFN-γ-stimulated) cells and (500 μg/mL RHP + LPS/IFN-γ-stimulated) cells are given. Differences between RH-A and RH-B are given in the right-side column.
| Protein | LPS/IFN- |
LPS/IFN- |
LPS/IFN- | RH-A versus RH-B | ||
|---|---|---|---|---|---|---|
| pg/mL ± stdev | pg/mL ± stdev |
| pg/mL ± stdev |
| ||
| CCL11/Eotaxin | 194 ± 7 | 150 ± 16 |
| 141 ± 15 |
| NSb |
| CCL2/MCP-1 | 1136 ± 126 | 1513 ± 145 |
| 837 ± 106 |
| 0.042 |
| CCL3/MIP-1 | 4028 ± 513 | 13050 ± 919 |
| 5455 ± 495 |
| 0.010 |
| CCL4/MIP-1 | 35500 ± 1697 | 93875 ± 1167 |
| 25800 ± 7354 |
| 0.009 |
| CXCL8/IL-8 | 30600 ± 3253 | 233250 ± 61165 |
| 155125 ± 74635 |
| NS |
| CCL5/RANTES | 11188 ± 1962 | 545 ± 91 |
| 353 ± 54 |
| NS |
| CXCL10/IP-10 | 37075 ± 11208 | 266 ± 27 |
| 228 ± 35 |
| NS |
|
| ||||||
| IL-1 | 7165 ± 1520 | 37800 ± 1980 |
| 18550 ± 1697 |
| 0.021 |
| IL-6 | 59975 ± 10006 | 47000 ± 6293 |
| 6525 ± 92 |
| 0.003 |
| IL-12 (p70) | 134 ± 17 | 31 ± 5 |
| 25 ± 7 |
| NS |
| IL-10 | 778 ± 84 | 845 ± 73 |
| 179 ± 16 |
| 0.010 |
| TNF- | 10515 ± 474 | 27325 ± 3712 |
| 6745 ± 983 |
| 0.044 |
| GM-CSF | 113 ± 10 | 212 ± 17 |
| 158 ± 8 |
| NS |
| G-CSF | 831 ± 165 | 14075 ± 2510 |
| 1272 ± 16 |
| 0.005 |
a P value: significance value between (LPS/IFN-γ) and (LPS/IFN-γ + substance) treatment.
bNS: not significant.
Figure 1Effect of RH on production of PGE2 and cytokines by activated peripheral blood leukocytes.
Effects of RHP on gene expression in stimulated PBL (cultured for 12 h). LPS/IFN-γ-stimulated cells were cultured with 125–500 μg/mL RHP for 12 h and gene expression was quantified by RT-PCR. Fold changes were calculated as indicated in Materials and Methods. Values for (LPS/IFN-γ-stimulated) cells and (500 μg/mL RHP + LPS/IFN-γ-stimulated) cells are given.
| Gene | LPS/IFN- |
LPS/IFN- |
LPS/IFN- | RH-A versus RH-B | ||
|---|---|---|---|---|---|---|
| Fold change | Fold change |
| Fold change |
| ||
| COX-2 | 83 | 107 | 0.061 | 81 | 0.739 | NSb |
| TNF- | 83 | 55 | 0.006 | 42 | 0.001 | NS |
| IL-1 | 3513 | 1347 | <0.001 | 859 | <0.001 | NS |
| IL-1 | 1460 | 538 | <0.001 | 410 | <0.001 | NS |
| IL-6 | 15928 | 9261 | 0.058 | 3656 | <0.001 | 0.04 |
|
| ||||||
| CCL5/RANTES | 1 | 0.8 | 0.070 | 0.8 | 0.054 | NS |
| CXCL8/IL-8 | 13 | 15 | 0.418 | 28 | <0.001 | 0.03 |
| CXCL10/IP-10 | 187 | 1 | <0.001 | <LODc | <0.001 | Not applicable |
| CXCL2/MIP-2 | 12 | 22 | 0.012 | 25 | 0.002 | NS |
| CCL20/MIP-3 | 3634 | 5454 | 0.014 | 6738 | 0.014 | NS |
a P value: significance value between (LPS/IFN-γ) and (LPS/IFN-γ + substance) treatment.
bNS: not significant.
cBelow level of detection.
Figure 2Effect of RH-A (straight line) and RH-B (dashed line) on gene expression in PBL. Cells were stimulated for 12 h with the indicated amount of substances and the gene expression was quantified by RT-PCR. Symbol on y-axis indicates the expression levels in LPS/IFN-γ only stimulated PBL. * P < 0.05, ** P < 0.01 (LPS/IFN-γ only versus LPS/IFN-γ+RH). † P < 0.05 and ‡ P < 0.01 indicate the differences between RH-A and RH-B.
Effects of RHP on catabolic gene expression in human primary chondrocytes. IL-1β-stimulated cells were cultured with 125–500 μg/mL RHP for 4 h and gene expression was quantified by RT-PCR. Fold changes were calculated as indicated in Materials and Methods. Values for (IL-1β stimulated) cells and (500 μg/mL RHP + IL-1β) stimulated cells are given.
| Gene | IL-1 |
IL- |
IL-1 |
| ||
|---|---|---|---|---|---|---|
| Fold change | Fold change |
| Fold change |
| ||
| MMP-1 | 28 | 16 | 0.001 | 26 | 0.620 | 0.032 |
| MMP-3 | 286 | 120 | 0.001 | 160 | 0.003 | NSb |
| MMP-13 | 1.7 | 0.2 | <0.001 | 0.5 | <0.001 | 0.040 |
| ADAMTS-4 | 10 | 5 | 0.006 | 8 | 0.295 | NS |
| CXCL2/MIP-2 | 467 | 122 | <0.001 | 180 | <0.001 | 0.091 |
| CXCL20/MIP-3 | 642 | 253 | 0.001 | 331 | 0.010 | NS |
| CCL5/RANTES | 176 | 127 | 0.008 | 151 | 0.241 | NS |
| CXCL8/IL-8 | 797 | 214 | <0.001 | 301 | <0.001 | 0.087 |
| IL-1 | 466 | 200 | 0.001 | 292 | 0.032 | NS |
| IL-6 | 1454 | 897 | 0.022 | 746 | 0.006 | NS |
| TNF- | 1120 | 1081 | 0.727 | 1704 | 0.005 | NS |
a P values: significance value between (IL-1β) and (IL-1β + substance) treatment.
bNot significant.
Figure 3Effect of RH preparations on expression levels in human primary chondrocytes. NHAC-kn cells were stimulated with IL-1β for 4 h and the expression levels of indicated genes were quantified by RT-PCR. Triangles on y-axis indicate the expression levels in IL-1β only treated NHAC-kn. Straight line: RH-A; dashed line RH-B. * P < 0.05, ** P < 0.01 (IL-β only versus IL-1β + RHP). † P < 0.05 and ‡ P < 0.01 indicate the differences between RH-A and RH-B.
Figure 4Principal component analysis showing the impact of different treatments and concentrations of RH-A and RH-B in peripheral blood leukocytes (upper panels) and normal human chondrocytes (bottom panel). PBLs were treated with LPS/IFN-γ alone or LPS/IFN-γ and RHP at the indicated concentrations (in μg/mL). NHAC-kn were activated with IL-1β alone or IL-1β and RHP at the indicated concentrations.